Latest Articles
Risk factors, survival analysis, and nomograms for high-grade endometrial stromal sarcoma patients with distant metastasis: A population-based study (2010-2019) - Frontiers
Risk factors, survival analysis, and nomograms for high-grade endometrial stromal sarcoma patients with distant metastasis: A population-based study (2010-2019) Frontiers
Published: Feb. 24, 2025, 1:38 p.m.
Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab - Physician's Weekly
Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab Physician's Weekly
Published: Feb. 4, 2025, 11:09 a.m.
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer - OncLive
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer OncLive
Published: Jan. 30, 2025, 10:54 p.m.
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? - Medscape
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? Medscape
Published: Jan. 21, 2025, 9:45 a.m.
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer - Physician's Weekly
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer Physician's Weekly
Published: Oct. 22, 2024, 6:31 a.m.
Pembrolizumab aids survival with high-risk endometrial cancer - Medical Xpress
Pembrolizumab aids survival with high-risk endometrial cancer Medical Xpress
Published: Oct. 21, 2024, 5:50 p.m.
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer - HealthDay
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer HealthDay
Published: Oct. 21, 2024, 3:35 p.m.
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint - Healio
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint Healio
Published: May 9, 2024, 7 a.m.
Molecular Classification May Predict Survival Outcomes in Endometrial Cancer - Oncology Learning Network
Molecular Classification May Predict Survival Outcomes in Endometrial Cancer Oncology Learning Network
Published: April 1, 2024, 7 a.m.
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy - The ASCO Post
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy The ASCO Post
Published: March 27, 2024, 6:45 p.m.
Link copied to clipboard!